Thrombocytosis in 715 Dogs (2011–2015)

Woolcock, Andrew D; Keenan, A. K.; Cheung, Chi-Ngai; Christian, John A.; Moore, George E.

doi:10.1111/jvim.14831

Cited by 38 publications

(53 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…; Matowicka‐Karna ; Woolcock et al . ). Previous studies in people have reported increases in platelet count and fibrinogen levels as a marker of inflammation and associated with more severe disease in various conditions including neoplasia, acute coronary syndrome, and inflammatory bowel disease (Odeberg et al .…”

Section: Discussionmentioning

confidence: 97%

“…However, future studies, including blood smears and flow cytometry, should be performed to assess this platelet increase and if there is any change to platelet function following RIV administration before drawing any specific conclusions regarding RIV's effect on platelets. Increases in platelet count are frequently associated with inflammation as well (Schafer 2001;Jagadesham et al 2014;Matowicka-Karna 2016;Woolcock et al 2017). Previous studies in people have reported increases in platelet count and fibrinogen levels as a marker of inflammation and associated with more severe disease in various conditions including neoplasia, acute coronary syndrome, and inflammatory bowel disease (Odeberg et al 2016;Suzuki (Morassi et al 2016) and therefore theoretically could worsen the underlying disease process.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs

Evans

Tansey

Wiebe

et al. 2019

Veterinary Medicine & Sci

View full text Add to dashboard Cite

The purpose of this study was to determine the effect of rivaroxaban (RIV) on haemostatic parameters assessed by prothrombin time (PT), activated partial thromboplastin time (aPTT) and kaolin‐activated thromboelastography (TEG) in apparently healthy dogs administered 1 mg kg−1 orally once daily for 1 week. Eleven dogs had a baseline complete blood count (CBC), fibrinogen, platelet count, serum chemistry profile, PT, aPTT, and TEG performed. Each dog was then administered approximately 1.0 mg kg−1 of RIV orally once daily for 1 week and the CBC, fibrinogen, platelet count, serum chemistry profile, PT, aPTT, and TEG was re‐evaluated. Any side effects attributed to RIV were noted at this time. One dog was excluded due to identification of a macrocytic thrombocytopenia on pre‐treatment blood work. The remaining 10 enrolled dogs completed the study. Dogs received a median dose of 1.02 mg kg−1 (range 0.94–1.17 mg kg−1) of RIV once daily and was associated with a significant increase in pulse, packed cell volume, total solids, platelet count, fibrinogen and a significant decrease in mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration. There was no significant change in PT, aPTT or any TEG parameters. The RIV appeared well tolerated with one dog having one episode of vomiting on day 4 but otherwise no other side effects were identified clinically or on recheck blood work. The results of this study suggests that RIV at a dose of 1 mg kg−1 orally once daily is safe and well tolerated but does not cause a significant prolongation of PT, aPTT or TEG parameters.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs

Evans

Tansey

Wiebe

et al. 2019

Veterinary Medicine & Sci

View full text Add to dashboard Cite

show abstract

“…The administration of these other myelosuppressive drugs at weekly intervals from vincristine treatments may have altered platelet counts. Prednisone was also administered at tapering doses during the first 4 weeks of treatment, which may be a potential confounder because thrombocytosis is commonly reported in dogs receiving corticosteroids (Woolcock et al 2017). The tumour burden was differed between the beginning of treatment and when remission was obtained.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the effect of vincristine on platelet count in dogs with lymphoma

Campbell

MacDonald

Dickinson

et al. 2019

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To determine the effect of vincristine administration on the platelet count, platelet morphology and incidence of thrombocytopenia in dogs diagnosed with lymphoma. Material and Methods Medical records of 59 dogs with lymphoma receiving vincristine sulphate were reviewed retrospectively. Results Following vincristine administration the platelet count was higher and the number of thrombocytopenic patients was lower. No difference was found in the number of dogs with enlarged and elliptical platelets following vincristine treatment. Clinical Significance Vincristine administration increases platelet counts in dogs with lymphoma. It is not contra‐indicated to administer vincristine to dogs with lymphoma that are thrombocytopenic.

show abstract

“…Thrombocytosis is a rare condition in dogs with malignant neoplasia [5], but typically occurs in humans with cancer [6]. However, there ports presented in the literature are conflicting, as some authors suggest that thrombocytopenia is the most common abnormality in dogs with malignant disease [5], while others indicate that thrombocytosis is a frequent abnormality in dogs with cancer [18,21,27]; thus, the true prevalence of thrombocytosis in animals with neoplasia might be underreported [5].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Hemostasis in Female Dogs with Mammary Carcinoma and the Influence of Clinical Stage and Histopathological Grade

Oliveira

Camplesi

Calazans

et al. 2019

Acta Scientiae. Vet.

View full text Add to dashboard Cite

Background: Mammary tumors are frequent in female dogs, and are biologically similar in female dogs and humans. Hemostatic disorders are common in humans with cancer, and the mechanisms that conduct coagulation activation involve tissue and cancer procoagulant factors and inflammatory cytokines. Despite the importance of coagulopathy diagnosis that evaluate hemostasis, veterinarians rarely request such tests in routine clinical oncology. This study aimed to investigate the possible hemostatic abnormalities in female dogs with mammary carcinomas and assess any associations with prognostic factors for mammary cancer in female dogs. Materials, Methods & Results:A total of 62 female dogs were selected for inclusion in this study regardless of age or breed. The control group consisted of 30 healthy dogs, and the carcinoma group consisted of 32 dogs with a histopathological diagnosis of mammary carcinoma that was free of distant metastases and comorbidities that could interfere with the hemostatic system integrity. The dogs with mammary carcinoma were divided into subgroups according to their histological type, histopathological grading, tumor size, and clinical stage of the disease (TNM) to evaluate the relationships between the subgroups and hemostatic parameters (blood platelet counts, prothrombin time [PT], activated partial thromboplastin time [aPTT], and plasma fibrinogen concentration). The hemostatic parameters were significantly higher in the carcinoma group than in the control group (P ≤ 0.05). These findings indicate that there is a strong association between the occurrence of mammary carcinoma and abnormal hemostatic parameters, as well as a strong association between histopathological grade I and normal hemostatic parameters. In addition, when evaluating subgroups, PT and aPTT values were significantly higher in dogs with histopathological grade II and III tumors than in dogs with histopathological grade I tumors. Furthermore, PT and aPTT values were higher in the clinical stage IV subgroup than in the remaining subgroups. Nonetheless, there was no statistical difference in these values among the clinical stage I, III, and IV subgroups. Discussion: Recent studies demonstrated that thrombocytosis is a common finding in dogs with cancer and that the true incidence of thrombocytosis might be underreported. The prolonged PT and aPTT observed in this study were higher than those described in the literature. The abnormalities in PT and aPTT values detected in female dogs with mammary carcinoma in this study might have been affected by the histopathological severity (grades II and III) and clinical disease stage. Hyperfibrinogenemia detected in the carcinoma group was the most common hemostatic abnormality. This finding was close to that found in the literature, in which 66.7% of female dogs presented with high fibrinogen values, which was more evident in dogs of clinical disease stages III and IV. The results indicate that 56% of animals presented with at least three hemostatic abnormalities, including the prolo...

show abstract

Thrombocytosis in 715 Dogs (2011–2015)

Cited by 38 publications

References 43 publications

A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs

A prospective evaluation of rivaroxaban on haemostatic parameters in apparently healthy dogs

Evaluation of the effect of vincristine on platelet count in dogs with lymphoma

Evaluation of Hemostasis in Female Dogs with Mammary Carcinoma and the Influence of Clinical Stage and Histopathological Grade

Contact Info

Product

Resources

About